Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Syros’ 98% Solution For Genomic Medicine

Executive Summary

Emerging Company Profile: Coming off its first partnership and a $43.2m IPO, Syros looks ahead to data later this year for its first two clinical candidates, both first-in-class agents that regulate gene expression.

You may also be interested in...



Syros Gets ‘Tyme’ To Bring Lead Candidate To Pivotal Readout

Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Incyte's Jakafi 1st drug OK'd in polycythemia vera

One day ahead of its Prescription Drug User Fee Act action date, Incyte's oral JAK1/JAK2 inhibitor Jakafi (ruxolitinib) won the FDA's approval in patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea – the first drug to gain that indication in the US.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC123367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel